Astrazeneca Plc · LSE:AZN
Astrazeneca — ESMO 2026 Investor Event
59 slides from Astrazeneca's conference presentation, Oct 26, 2026
Slide 1: Meet AZN Management: ESMO 2026
Meet AZN Management: ESMO 2026 Investor Event 26 October 2026
Slide 2: Cautionary statements regarding forward-looking statements
Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certai
Slide 3: AstraZeneca @ ESMO 2026
AstraZeneca @ ESMO 2026 Dave Fredrickson Opening remarks EVP, Oncology Haematology Business Bladder cancer: Expanding the foundational role of Prof. Thomas Powles Imfinzi across MIBC Professor of Genitourinary Oncology, Barts Including Q&A session Cancer Institute EGFRm lung cancer: Extending Tagris
Slide 4: Unprecedented >140 abstract acceptances at ESMO and WCLC 2026
>140 abstract >110 poster 38 oral acceptances presentations presentations at ESMO and WCLC 2026 Unprecedented 4 Presidential datasets at ESMO VOLGA SAFFRON DeLLphi-305 CLARITY-Gastric01 Imfinzi Tagrisso + Orpathys Imfinzi sone-ve LBA2 LBA6 LBA3 LBA7 2 practice-changing Phase III datasets Additional
Slide 5: Bladder cancer: Expanding the foundational role of Imfinzi across MIBC
Bladder cancer: Expanding the foundational role of Imfinzi across MIBC Prof. Thomas Powles PROFESSOR OF GENITOURINARY ONCOLOGY, BARTS CANCER INSTITUTE
Slide 6: VOLGA – expanding the role of Imfinzi in MIBC
VOLGA – expanding the role of Imfinzi in MIBC Neoadjuvant Adjuvant Imfinzi Q3W × 3 cycles Imfinzi Q4W × 9 cycles Dual primary endpoint: Imfinzi + EV – MIBC (cT2- – EFS¹: Imfinzi + EV vs control N=233 Enfortumab vedotin T4aN0/1M0 or – EFS¹: Imfinzi + Imjudo + EV vs Q3W × 3 cycles cT1N1M0) by local co
Slide 7: VOLGA – significant improvement in EFS vs control
VOLGA – Imfinzi + EV demonstrated a statistically significant improvement in EFS vs control Imfinzi + EV Control N=233 N=229 100 Events, n (%) 84 (36) 123 (54) Median EFS, mo (95% CI) NR (33.2–NC) 12.1 (7.6–27.0) HR (95% CI) 0.51 (0.38–0.67) 80 Stratified log-rank P value1 <0.0001 73% Event-free sur
Slide 8: VOLGA – significant improvement in OS vs control
VOLGA – Imfinzi + EV demonstrated a statistically significant improvement in OS vs control 100 87% 78% 80 81% Overall survival (%) 60 69% 40 Imfinzi + EV Control N=233 N=229 Deaths, n (%) 49 (21) 74 (32) 20 Median OS, mo (95% CI) NR (NC–NC) NR (37.7–NC) HR (95% CI) 0.58 (0.40–0.83) Median follow-up
Slide 9: VOLGA – consistent OS benefit across subgroups
VOLGA – consistent OS benefit across subgroups Events/patients Subgroup Category Imfinzi + EV Control HR (95% CI) All patients 49/233 74/229 0.58 (0.40–0.83) Age at randomisation <65 years 6/49 11/40 NC NC (NC–NC) ≥65 years 43/184 63/189 0.64 (0.43–0.95) Sex Male 38/191 53/187 0.64 (0.42–0.96) Femal
Slide 10: VOLGA – improved pCR rate and ctDNA clearance
VOLGA – Imfinzi + EV improved pCR rate vs control, with 60% ctDNA clearance in baseline ctDNA+ patients Exploratory analysis: ctDNA status in matched evaluable Local pathology review (ITT)1 samples at baseline and pre-RC = 112 patients2 Risk ratio, 4.7 Baseline Pre-RC (95% CI, 3.1–7.3) 60 Neoadjuvan
Slide 11: VOLGA – safety profile consistent with individual agents
VOLGA – safety profile for Imfinzi + EV consistent with the safety profiles of the individual agents Imfinzi + EV Control Events, n (%) n=228 n=229 Imfinzi + EV arm (n=228) Control arm (n=229) AEs of any cause 227 (>99) 170 (74) Pruritus 44 0.9 4 Maximum Grade 3 or 4 AEs 145 (64) 101 (44) Urinary tr
Slide 12: VOLGA – Imfinzi as a foundational treatment across early bladder cancer
VOLGA – Imfinzi as a foundational treatment across early bladder cancer ― Perioperative Imfinzi + 3 cycles of neoadjuvant enfortumab vedotin significantly improved EFS and OS vs control ― EFS HR 0.51 (95% CI, 0.38–0.67) P<0.0001, and OS HR 0.58 (95% CI, 0.40–0.83) P=0.0027 ― Benefits were consistent
Slide 13: Opportunity for Q&A
Opportunity for Q&A Key External Expert Prof. Thomas Powles PROFE SSOR O F GE NIT OURINARY ONCOL OGY, BAR TS CANCE R INS TIT UT E AstraZeneca Leadership Pascal Soriot Dave Fredrickson E VP, ONCOLO GY CH IEF E XECUTI VE O FFICE R HAE MATOL OGY BUSINE SS Susan Galbraith Leora Horn E VP, ONCOLO GY SVP,
Slide 14: EGFRm lung cancer: Extending Tagrisso as backbone therapy
EGFRm lung cancer: Extending Tagrisso as backbone therapy Prof. Yi-Long Wu PROFESSOR OF ONCOLOGY, GUANGDONG LUNG CANCER INSTITUTE
Slide 15: SAFFRON – Tagrisso + Orpathys in post-TKI EGFRm NSCLC
SAFFRON – Tagrisso + Orpathys potential first biomarker- driven, all-oral therapy for post-TKI EGFRm NSCLC – EGFRm1 locally advanced Primary endpoint: or metastatic NSCLC Tagrisso 80 mg QD ― PFS (BICR) in the FAS – MET overexpression + Orpathys 300 mg BID4 (MET IHC3+≥90%) Key secondary/exploratory R
Slide 16: SAFFRON – significantly improved PFS vs SoC
SAFFRON – Tagrisso + Orpathys significantly improved PFS vs SoC 100 Tagrisso Platinum– 90 + Orpathys pemetrexed Progression-free survival (%) 80 Median PFS, mo (95% CI) 7.6 (5.6–9.7) 5.4 (4.2–5.8) 70 60 HR (95% CI) 0.55 (0.42–0.72) 50 P value p<0.001 40 36% 30 20 10% 10 0 0 1 2 3 4 5 6 7 8 9 10 11 1
Slide 17: SAFFRON – significant OS improvement vs SoC
SAFFRON – significant 4.9-month OS improvement with Tagrisso + Orpathys vs SoC Tagrisso Platinum– 100 + Orpathys pemetrexed 90 Median OS, mo (95% CI) 17.8 (15.6–23.7) 12.9 (10.6–16.8) 80 70% 70 HR (95% CI) 0.68 (0.50–0.91) Overall survival (%) 60 53% P value p=0.0101 50 40 30 20 10 0 0 1 2 3 4 5 6 7
Slide 18: SAFFRON – safety profile
SAFFRON – safety profile for Tagrisso + Orpathys consistent with the known profiles of each medicine Tagrisso + Platinum– Tagrisso + Orpathys Platinum–pemetrexed Orpathys pemetrexed (n = 170) (n = 145) Peripheral oedema 49 8 8 Anaemia 26 5 18 54 Median total duration of exposure, mo Diarrhoea 26 1 8
Slide 19: SANOVO – exploring Tagrisso + Orpathys in 1L setting
SANOVO – exploring potential of Tagrisso + Orpathys in 1L setting – EGFRm untreated unresectable or metastatic Orpathys 300 mg/200 mg BID (by BW) Primary endpoint: NSCLC1 + Tagrisso 80 mg QD ― PFS (inv.) – Centrally confirmed MET overexpression2 R Secondary endpoints: 1:1 – IHC 3+ ≥90%3 or ― PFS (IR
Slide 20: SANOVO – Tagrisso + Orpathys significantly improved PFS
SANOVO – Tagrisso + Orpathys significantly improved PFS1 MET IHC 3+ population ITT population Tagrisso Tagrisso Tagrisso Tagrisso + Orpathys + Orpathys 100 N = 98 100 N = 164 N = 98 N = 162 90 mPFS (95% 90 mPFS (95% 76.0% 24.8 (19.4–27.6) 11.1 (8.3–16.6) 24.9 (22.0–27.6) 13.8 (10.9–16.6) Progression
Slide 21: SANOVO – clinical benefit in overall survival
SANOVO – very encouraging clinical benefit in overall survival with Tagrisso + Orpathys Tagrisso Tagrisso + Orpathys N = 164 N = 162 100 94.4% Number of deaths, n (%)1–2 49 (30.2) 83 (50.6) 90 Median OS, mo (95% CI) 44.5 (41.3–NE) 34.9 (26.3–41.1) 79.8% HR (95% CI) 0.48 (0.33–0.68) 80 70 81.0% 67.4%
Slide 22: SANOVO – safety consistent with known profiles
SANOVO – safety remains consistent with known profiles Tagrisso Tagrisso + Orpathys Tagrisso Tagrisso + Orpathys N = 164 Peripheral oedema 65 7 7 N = 162 Hypoalbuminaemia 63 1 22 Platelet count decreased 51 2 2 32 Median exposure, mo (range) 22.1 (0.4–44.2) 12.9 (0.4–45.5) Anaemia 49 6 2 40 Blood cr
Slide 23: SAFFRON and SANOVO – reinforcing role of backbone Tagrisso
SAFFRON and SANOVO – reinforcing role of backbone Tagrisso across lines of treatment for EGFRm NSCLC ― SAFFRON: Tagrisso + Orpathys demonstrated statistically significant and clinically meaningful improvements in PFS and OS vs platinum–pemetrexed in EGFRm MET-overexpressed and/or -amplified post-TKI
Slide 24: Small cell lung cancer: Reinforcing Imfinzi as backbone therapy across SCLC
Small cell lung cancer: Reinforcing Imfinzi as backbone therapy across SCLC Leora Horn SVP, LATE DEVELOPMENT ONCOLOGY
Slide 25: DeLLphi-305 – Imfinzi with Imdelltra in ES-SCLC
DeLLphi-305 – further reinforcing key role of Imfinzi in ES-SCLC with new data in combination with Imdelltra® Until progression or unacceptable toxicity Primary endpoint Imfinzi (1500 mg Q4W) 3 ― OS ― Age ≥18 years + Imdelltra® (tarlatamab) (10 Imfinzi1 ― No disease progression mg Q2W)2 | n=282 Key
Slide 26: DeLLphi-305 – significant OS improvement
DeLLphi-305 – significant OS improvement with Imfinzi + Imdelltra® vs Imfinzi alone Imfinzi + Imdelltra® Imfinzi (n=281) (n=282) 100 Median OS, mo 21.1 12.7 92% (95% CI) (20.8–NE) (11.2–14.8) 79% HR (95% CI) 0.42 (0.32–0.54) 80 P value (2-sided) <0.001 Overall survival (%) 60 75% 40 53% 20 0 0 3 6 9
Slide 27: DeLLphi-305 – PFS improvement
DeLLphi-305 – more than 5-month PFS improvement with Imfinzi + Imdelltra® vs Imfinzi alone Imfinzi + Imfinzi Imdelltra® (n=281) 100 (n=282) Median PFS, mo 7.4 1.9 (95% CI) (5.6–9.1) (1.9–2.0) 80 HR (95% CI) 0.34 (0.28–0.42) Progression-free P value (2-sided) <0.001 survival (%) 60 53% 38% 40 20 17%
Slide 28: DeLLphi-305 – manageable safety profile
DeLLphi-305 – manageable safety profile consistent with the individual agents Imfinzi + Imfinzi Events, n (%) Imdelltra® (n=278) (n=282) Median treatment duration, weeks (IQR) 46.9 (16.4–65.6) 8.1 (4.1–20.1) Any TEAE 281 (99.6) 258 (92.8) – CRS and ICANS consistent with the known safety Grade ≥3 TEA
Slide 29: DeLLphi-305 – first dual IO regimen in ES-SCLC
DeLLphi-305 – Imfinzi + Imdelltra® first dual IO regimen in ES-SCLC, reinforcing the role of Imfinzi in this setting ― Imfinzi + Imdelltra® significantly improved OS, PFS and ORR vs Imfinzi in patients with ES-SCLC without progression after initial CTx + Imfinzi ― 58% reduction in the risk of death
Slide 30: Gastric cancer: Unlocking the power of ADCs with sone-ve
Gastric cancer: Unlocking the power of ADCs with sone-ve Susan Galbraith EVP, ONCOLOGY HAEMATOLOGY R&D
Slide 31: Rapidly advancing broad high-value portfolio of ADCs
Rapidly advancing broad high-value portfolio of ADCs Clinical-stage ADC pipeline spans multiple Expanding Phase III development for late- targets across solid and haematologic stage ADCs tumour types CLARITY-Gastric01 Phase I Phase II Phase III 2L+ Claudin 18.2+ gastric cancer CLARITY-Gastric02 CLDN
Slide 32: ADC portfolio value through collaboration with Summit
Enhancing the value of AstraZeneca’s ADC portfolio through strategic collaboration with Summit Datroway + Other AZ sone-ve + ivonescimab assets + ivonescimab ivonescimab Gastrointestinal cancers Breast and lung cancers Planned collaboration – Broadens and maximises AZ assets across key tumour types
Slide 33: Maximising AstraZeneca ADCs with next-generation IO bispecifics
Maximising the potential of AstraZeneca ADCs through combinations with next-generation IO bispecifics Illustrative of ADC value only; not to scale Early leadership with monotherapy Maximisation with and combinations with SoC next-generation IO Through external partnership 1 AZ-owned Monotherapy, sma
Slide 34: CLARITY-Gastric01 – study design
CLARITY-Gastric01 – establishing sone-ve in gastric cancer with positive overall survival data DOSE SELECTION Study population: Dual primary endpoints: – 2L+ GEC expressing CLDN18.2 (≥25% – OS (3L+2) tumour cells with any intensity sone-ve 2.2 mg/kg Q3W (n=267) – PFS by BICR (ITT3) membranous staini
Slide 35: CLARITY-Gastric01 – 53% reduction in risk of death in 3L+
CLARITY-Gastric01 – sone-ve reduced the risk of death by 53% vs investigator’s choice of therapy in 3L+ Investigator's 100 sone-ve choice 2.2 mg/kg 90 of therapy (n=178) 80 (n=177) Overall survival (%) 70 Median OS, mo (95% CI) 10.0 (7.2–11.4) 5.0 (4.2–6.4) 60 HR (95% CI) 0.47 (0.36–0.62) 50 38.1% P
Slide 36: CLARITY-Gastric01 – 42% reduction in risk of death in 2L+
CLARITY-Gastric01 – sone-ve reduced the risk of death by 42% vs investigator’s choice of therapy in 2L+ Investigator's 100 sone-ve 2.2 choice 90 mg/kg (n=267) of therapy (n=265) 80 Median OS, mo (95% CI) 10.6 (9.1–12.0) 6.4 (5.8–7.6) Overall survival (%) 70 60 HR (95% CI) 0.58 (0.47–0.73) 50 42.6% P
Slide 37: CLARITY-Gastric01 – OS subgroup analysis in 2L+
CLARITY-Gastric01 – exploratory analysis shows favourable OS HR point estimates across most subgroups in 2L+ No. of events/total no. of patients HR Subgroup sone-ve Investigator’s (95% CI) 2.2 mg/kg choice of therapy All patients 139/267 (52.1) 174/265 (65.7) 0.58 (0.47–0.73) Age: ≥18–<65 years 96/1
Slide 38: CLARITY-Gastric01 – safety profile vs ICT
CLARITY-Gastric01 – differentiated and manageable safety profile vs ICT Investigator’s choice Investigator’s sone-ve (n=261) Sone-Ve of therapy (n=252) choice 2.2 mg/kg of therapy (n=261) Nausea 54.4% 6.9% 2.8% 26.6% (n=252) Median (range) duration of exposure, Decreased appetite 43.3% 9.6% 1.6% 24.
Slide 39: CLARITY-Gastric01 – improves OS in 2L+ setting
CLARITY-Gastric01 – sone-ve improves OS with a manageable safety profile in the 2L+ setting ― sone-ve significantly improved OS vs investigator’s choice of therapy in advanced or metastatic CLDN18.2-positive gastro-oesophageal carcinoma ― 53% reduction in the risk of death in 3L+ and 42% in 2L+ ― Me
Slide 40: Realising our ambition in Oncology
Realising our ambition in Oncology Dave Fredrickson EVP, ONCOLOGY HAEMATOLOGY BUSINESS
Slide 41: Transforming treatment in CLDN18.2+ gastric cancers
Transforming treatment in CLDN18.2+ gastric cancers CLARITY-Gastric01 | First global study to show OS Moving earlier and broader benefit in broad 2L+ CLDN18.2+ population with sone-ve >50k patients across the G7 2L+ HER2-negative 1L metastatic gastric cancer >200k patients in China gastric cancer Lo
Slide 42: VOLGA reinforces Imfinzi as a backbone in bladder cancer
VOLGA reinforces Imfinzi as a backbone in bladder cancer VOLGA | Consolidating the role of Imfinzi Expanding presence in bladder cancer with across the spectrum of MIBC broad Imfinzi coverage Patient-focused, differentiated regimen NMIBC MIBC Strong efficacy with EV exposure only in neoadjuvant sett
Slide 43: Strengthening position in EGFRm NSCLC with Tagrisso + Orpathys
Strengthening position in EGFRm NSCLC with Tagrisso + Orpathys combinations SAFFRON | Only global trial to demonstrate Tagrisso combination pipeline ensures significant OS in this setting continued leadership 45k patients across the G7 Establishing novel combinations in 2L+ | 2L+ NSCLC 210k patients
Slide 44: AstraZeneca in EGFRm non-small cell lung cancer
AstraZeneca in EGFRm non-small cell lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1st line 2nd line + Est. epi (G7, 2026) ~28K ~11K ~9K ~15K ~51K ~43K Tagrisso +/- CTx Datroway FLAURA, FLAURA2 TROPION-Lung05 Exon 19 deletions / exon 21 Tagrisso SBRT → Tagrisso
Slide 45: Continuing to reshape management of SCLC with Imfinzi-based regimens
Continuing to reshape management of SCLC with Imfinzi-based regimens DeLLphi-305 | First dual IO regimen and Ongoing development programme for Imfinzi potential new SoC in ES-SCLC in SCLC High unmet need Limited-stage SCLC Extensive-stage SCLC Current survival outcomes remain ~1 year CRT → Imfinzi C
Slide 46: Looking to the future of AstraZeneca
Looking to the future of AstraZeneca Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 47: Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth
Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth Beyond 2030 Working on “today, tomorrow and the day after” ADCs and Radioconjugates Illustrative only, not to scale Cell therapy and T-cell engagers Launching key NMEs $80bn Gene therapy AZD0120 saruparib Etcamah surovatamig Next-genera
Slide 48: Twelve positive Phase III programme readouts YTD
Twelve positive Phase III programme readouts YTD OBERON efzimfotase CHESTNUT tozorakimab Imfinzi COPD TITANIA alfa MULBERRY locoregional HCC EMERALD-3 MIRANDA HPP HICKORY Ultomiris Imfinzi sone-ve ICAN VOLGA CLDN18.2+ 2L+ CLARITY-Gastric01 IgAN MIBC gastric cancer Tagrisso + Imfinzi Enhertu 1L uroth
Slide 49: NMEs with pivotal data readouts before 2030 drive growth
NMEs with pivotal data readouts before 2030 drive growth into and through the next decade >$5bn $3-5bn 1 sonesitatug vedotin2 AZD0120 volrustomig balcinrenone | zibotentan + cliramitug saruparib dapagliflozin surovatamig elecoglipron | AZD6234 | AZD9550 efzimfotase alfa rilvegostomig laroprovstat fr
Slide 50: Pipeline momentum continues through 2027
Pipeline momentum continues through 2027 Key readouts support NME growth outlook >15 other high-value readouts NME NRA PYR1 TROPION-Lung07 | Datroway Datroway AVANZAR H1 TROPION-Lung15 | Datroway ± Tagrisso $5bn+ 1L NSQ/NSQ TROP2+ NSCLC PACIFIC-9 | Imfinzi + oleclumab/monalizumab H1 reAZURE-PLUS | l
Slide 51: Opportunity for Q&A
Opportunity for Q&A Pascal Soriot Dave Fredrickson E VP, ONCOLO GY CH IEF E XECUTI VE O FFICE R HAE MATOL OGY BUSINE SS Susan Galbraith Leora Horn E VP, ONCOLO GY SVP, L ATE DEVE LOPMENT HAE MATOL OGY R& D ONCOL OGY Sunil Verma SVP, GL OBAL HE AD, ONCOL OGY FRANCHIS E 52
Slide 52: Appendix
Meet AZN Management: ESMO 2026 APPENDIX
Slide 53: Glossary
Glossary • 1L, 2L, 3L (a)BTC ADC adj. first-, second-, third-line (advanced) biliary tract cancer antibody-drug conjugate adjuvant FRα FSI G7 gBRCAm folate receptor alpha first subject in Group of Seven (major pharmaceutical markets) germline BRCA mutation NR NSCLC NSQ NST not reached non-small cell
Slide 54: AstraZeneca in non-small cell lung cancer
APPEN DI X | Oncology tumour maps AstraZeneca in non-small cell lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1st line 2nd line + Est. epi (G7, 2026) ~152K ~70K ~54K ~99K ~310K ~262K Imfinzi + Imjudo + CTx POSEIDON CRT → Imfinzi Datroway + IO ± platinum AVANZAR
Slide 55: AstraZeneca in EGFRm non-small cell lung cancer
APPEN DI X | Oncology tumour maps AstraZeneca in EGFRm non-small cell lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1st line 2nd line + Est. epi (G7, 2026) ~28K ~11K ~9K ~15K ~51K ~43K Tagrisso +/- CTx Datroway FLAURA, FLAURA2 TROPION-Lung05 Exon 19 deletions /
Slide 56: AstraZeneca in breast cancer
APPEN DI X | Oncology tumour maps AstraZeneca in breast cancer Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7, 2026) 540k 135k 100k 70k 55k HER2-positive Enhertu → THP NST residual disease → Enhertu Enhertu ± pertuzumab Enhertu Enhertu 15-20% DESTINY-Breas
Slide 57: AstraZeneca in gastric cancer
APPEN DI X | Oncology tumour maps AstraZeneca in gastric cancer Early Advanced/Metastatic Stage II/III/IVa 1st line 2nd line 3rd line Est. epi (G7, 2026) 50k 90k 60k 30k Enhertu + rilvegostomig + FP HER2-positive ARTEMIDE-Gastric01 Enhertu Enhertu 20% DESTINY-Gastric02, 04 DESTINY-Gastric01 Enhertu
Slide 58: AstraZeneca in bladder cancer
APPEN DI X | Oncology tumour maps AstraZeneca in bladder cancer High-risk NMIBC MIBC 1L mUC Est. epi (G7, 2026) 149k 81k 63k Neoadjuvant Imfinzi + EV ± Imjudo → adjuvant Imfinzi ± Imjudo VOLGA Neoadjuvant Imfinzi + CTx Imfinzi + BCG induction and maintenance → adjuvant Imfinzi Imfinzi + CTx ± Imjudo
Slide 59: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorised use or dis